Valeant planning hostile bid for Allergan

This March 20, 2002 file photo shows a vial of Botox, made by Allergan. Valeant Pharmaceuticals on Tuesday, June 17, 2014 said it plans to take a buyout offer for Allergan directly to its shareholders this week, as the Botox maker continues to rebuff its proposals. (AP Photo/Damian Dovarganes, File)

Valeant plans to take a buyout offer for Allergan directly to its shareholders this week, as the Botox maker continues to rebuff its proposals that have risen as high as $53 billion.

Valeant Pharmaceuticals International Inc. Chairman and CEO J. Michael Pearson said in a conference call Tuesday that proxies seeking support for its bid may be mailed in "the near-term."

"It is clear Allergan's management and their board will never sit down and act in the interest of their shareholders," he said.

Canadian-based Valeant has teamed with Bill Ackman's Pershing Square Capital Management to try to purchase Allergan. The two companies went public with their takeover attempt in April and have increased their offer several times.

Allergan Inc. has repeatedly rejected the offers as underpriced and risky. But Pearson said that Valeant believes an Allergan vote would "be overwhelmingly in support of the deal."

Valeant and Pershing—which has a 9.7 percent stake in Allergan—have continued to pursue Allergan despite the Irvine, California company's disinterest. The latest offer was worth about $53 billion. Allergan's market capitalization was about $48 billion in midday trading Tuesday.

Ackman previously said he would move to replace most of Allergan's board of directors as part of the battle for control of the company. Pearson said Tuesday that Pershing is looking to call a special shareholders meeting to remove six of Allergan's nine board members. Last week Pershing filed a lawsuit to confirm that its push for the special meeting won't trigger a defensive "poison pill" from Allergan.

Allergan adopted a one-year shareholder rights plan after Valeant and Pershing announced their bid in April. Under the plan, if any person or group acquires a 10 percent or greater stake in the company, other stock owners would be allowed to acquire additional shares at a discounted rate.

Pearson said that a special meeting of Allergan shareholders could be held in August, but should take place by year's end.

An email to Allergan for comment was not immediately returned.

Allergan's stock added $1.71, or 1.1 percent, to $161.07 in midday trading Tuesday, while shares of Valeant rose $1.95, or 1.7 percent, to $119.70.

Related Stories

Valeant raises cash-stock offer for Allergan (Update)

date May 28, 2014

Valeant Pharmaceuticals has pumped more cash into its bid for Botox maker Allergan, and it also defended its business model on Wednesday, a day after its reluctant acquisition target aired more concerns about ...

Recommended for you

Game shows mosquito's-eye view of malaria

date 22 hours ago

A new game about the life cycle of malaria that can be played on Android smartphones has been created by an Oxford University developer, based on malaria research at the University's Nuffield Department of ...

DMV program can generate additional organ donors

date Apr 23, 2015

(HealthDay)—A brief, web-based training program for department of motor vehicles (DMV) employees that educates them about organ and tissue donation can increase the likelihood of customers registering as ...

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.